30458-68-5

Basic information

• Product Name: 2-Chloro-3-Methyl-3H-iMidazo[4,5-b]pyridine
• Synonyms: 2-Chloro-3-Methyl-3H-iMidazo[4,5-b]pyridine
• CAS NO: 30458-68-5
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Mol File: 30458-68-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 65-67 °C
• Boiling Point: 321.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.80±0.30(Predicted)
• CAS DataBase Reference: 2-Chloro-3-Methyl-3H-iMidazo[4,5-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-Methyl-3H-iMidazo[4,5-b]pyridine(30458-68-5)
• EPA Substance Registry System: 2-Chloro-3-Methyl-3H-iMidazo[4,5-b]pyridine(30458-68-5)

Safety Data

• Hazardous Substances Data: 30458-68-5(Hazardous Substances Data)

Upstream product

• 6298-19-7 2-chloro-3-aminopyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 6688-61-5 3-methyl-3H-imidazo[4,5-b]pyridine 
• 5028-20-6 3-amino-2-methylaminopyridine 
• 21991-39-9 3-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 
• 1281006-64-1 N-benzyl-N-methyl-3-nitropyridin-2-amine 

Downstream Products

• 30458-69-6 3-methyl-3H-imidazo[4,5-b]pyridin-2-amine 
• 1042154-06-2 C₁₈H₂₁N₅ 

Relevant articles and documents

-

-

FUSED HETEROCYCLIC COMPOUNDS

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones

A series of imidazopyridine thiazolidine-2,4-diones were designed and synthesized from their corresponding pyridines. These compounds represent conformationally restricted analogues of the novel hypoglycemic compound rosiglitazone (5). The series was evaluated for its effect on insulin-induced 3T3-L1 adipocyte differentiation in vitro and its hypoglycemic activity in the genetically diabetic KK mouse in vivo. The structure-activity relationships are discussed. On the basis of the in vivo potency, 5-[4-(5-methoxy-3-methyl-3H-imidazo[4,5-b]pyridin-2-ylmethoxy)ben zyl]thiazolidine-2,4-dione (19a) was selected as the candidate for further studies in a clinical setting.